Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Vaccine volatility

Assessing fallout from vaccine scandal, trade war on Chinese biopharma stocks

August 17, 2018 10:33 PM UTC

The last two weeks have not been kind to biopharma companies listed on Chinese exchanges, and Thursday’s announcements regarding the resignations of officials over a vaccine scandal could further dampen sentiment.

Earlier this month, the Shenzhen Stock Exchange publicly reprimanded six senior executives at Changsheng Bio-Technology Co. Ltd. (SZSE:002680) after the company allegedly violated manufacturing quality controls by falsifying production records for freeze-dried human rabies vaccines (see “Safety, Trade Concerns Weigh on China Biotechs”)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article